Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer-Reference-Cited by-同舟云学术

Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer

Published:2015-06 Issue:6 Volume:23 Page:1123-1130
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Barve Minal,Wang Zhaohui,Kumar Padmasini,Jay Christopher M,Luo Xiuquan,Bedell Cynthia,Mennel Robert G,Wallraven Gladice,Brunicardi Francis Charles,Senzer Neil,Nemunaitis John,Rao Donald D

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference41 articles.

1. Discrete states of a protein interaction network govern interphase and mitotic microtubule dynamics;Niethammer;PLoS Biol,2007

2. Stathmin prevents the transition from a normal to an endomitotic cell cycle during megakaryocytic differentiation;Iancu-Rubin;Cell Cycle,2005

3. The stathmin phosphoprotein family: intracellular localization and effects on the microtubule network;Gavet;J Cell Sci,1998

4. Stathmin: a protein with many tasks. New biomarker and potential target in cancer;Belletti;Expert Opin Ther Targets,2011

5. Proof concept for clinical justification of network mapping for personalized cancer therapeutics;Nemunaitis;Cancer Gene Ther,2007

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Situ Vaccine: Breaking the Traditional Vaccine Paradigm;New Topics in Vaccine Development [Working Title];2023-11-17

2. Nanomedicines for hepatocellular carcinoma therapy: Challenges and clinical applications;Materials Today Communications;2023-03

3. Lipid‐based nucleic acid therapeutics with in vivo efficacy;WIREs Nanomedicine and Nanobiotechnology;2022-09-30

4. Magnetically responsive nanoplatform targeting circRNA circ_0058051 inhibits hepatocellular carcinoma progression;Drug Delivery and Translational Research;2022-09-16

5. Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks;Cell Cycle;2022-06-14